Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0YO4Q)

Drug Name

Urocortin 2 Drug Info

Synonyms

Urocortin 2; Urocortin II; Urocortin-2; 351999-18-3

Indication

Disease Entry	ICD 11	Status	REF
Congestive heart failure	BD10	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Corticotropin-releasing factor receptor 2 (CRHR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RT-400	DM8DVC9	Acute decompensated heart failure	BD1Z	Phase 2	[3]
NBI-34041	DM5BQK3	Eating disorder	6B82	Phase 1	[4]
PF-572778	DMZ8HW7	Generalized anxiety disorder	6B00	Terminated	[5]
SC-241	DM7I6VO	Anxiety disorder	6B00-6B0Z	Terminated	[6]
astressin	DMSFLTK	Discovery agent	N.A.	Investigative	[7]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Corticotropin-releasing factor receptor 2 (CRHR2)	TTIY658	CRFR2_HUMAN	Antagonist	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 927).
2	Evolution of complementary peptide systems: teneurin C-terminal-associated peptides and corticotropin-releasing factor superfamilies. Ann N Y Acad Sci. 2009 Apr;1163:215-20.
3	Advances in therapeutic peptides targeting G protein-coupled receptors. Nat Rev Drug Discov. 2020 Jun;19(6):389-413.
4	Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36.
5	WO patent application no. 2013,1603,15, Genetic predictors of response to treatment with crhr1 antagonists.
6	US patent application no. 2015,0094,310, Crhr1 antagonists for use in the treatment of patients having crh overactivity.
7	Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of corticotropin-releasing factor receptors. J Pharmacol Exp Ther. 1999 Feb;288(2):729-34.